# Using early health economic models to support drug development decisions

**Richard Nixon** 

Economic Modeling, Advanced Quantitative Sciences, Novartis Joint BBS and EFSPI Seminar on Health Technology Assessment 2013 June 4



## Health Economic Models can support drug development decisions

- Health economics models are used for demonstrating the value of a drug to payers post-registration
- Health economic models can be used to support drug development decisions
  - Development decisions and Phase III trials should also focus on HTA considerations as well as drug registration
- Decisions and concerns during drug development are different from those for reimbursement
  - Leading to different models and metrics



## Burman and Wiklund framework for modeling

Powerful generic guidelines that can be used to think about HE models

#### Framing

 (1) Good modeling is about making better decisions and (2) is driven by the underlying question

#### Data integration

 (3) Good modeling is based on applied sciences and (4) uses a diversity of information sources

#### Continuous parsimony

 (5) Good modeling is not made unnecessarily complicated and (6) is a continuous process

#### Communication

• (7) Good modeling facilitates communication



### Case study

Support development decisions of a new drug

- A pharmaceutical company has a new drug in development
  - A dose range finding study is currently underway
  - Confirmatory registration studies are being planned
- This drug is a treatment for a recurrent event disease
  - Events are acute and life threatening
- Development plan should consider reimbursement in addition to registration




## Good modeling is about making better decisions and is driven by the underlying question

- Don't model unless you see which decision could be improved by your model
- Failure to do so can lead to work that is unfocused leaving the decision maker with the question "so what?"



#### A decision hierarchy identifies issues to be decided and issues already decided or that can be deferred



- Policy
- Environment
- Decisions already made
- Near- and long-term strategic direction
- Near-term significant resource commitments
- Issues that must be resolved today
- Later significant resource commitments
- Decisions for specialists
- Operational or tactical decisions



## Decisions for reimbursement are different from decisions during drug development

	Reimbursement	Development
Decision perspective	Payer	Sponsor
Decision	<ul> <li>Do I reimburse this drug?</li> <li>In which patients?</li> <li>Which other treatments should have already been tried?</li> </ul>	<ul> <li>Should development be continued?</li> <li>What level of efficacy is required to demonstrate cost-effectiveness?</li> <li>Which patient population should be targeted?</li> <li>What price should be charged for the drug?</li> <li>What information do I need to collect during Phase III development?</li> </ul>
Metrics	<ul><li>ICER</li><li>CEAC</li><li>Budget impact</li></ul>	<ul><li>Value of information</li><li>Drug price</li><li>Sensitivity analysis</li></ul>



## Model should not try to answer everything, but be tailored to the specific problem

- Should development be continued?
  - What price could be justified for the drug to be cost-effective?
  - Is there a cost-effective sub-population?
- What do we need to measure in the development program if we continue?
  - What are the key value drivers of the drug?




#### Good modeling is based on applied sciences and uses a diversity of information sources

- Aim for a portfolio of inter-related skills and rather than fragmentation of role into ever smaller pieces
- A good modeler is a translational scientist capable of understanding the problem, translating it to a model, and communicating back the results



### What is a model?

A way to simplify reality, synthesis information, and communicate decisions



- "A model is a mathematical construct to mimic reality, built based on data, … and the current scientific understanding of the process involved."
  - A model is always a simplification



Find the best model for the purpose, considering the available data and the decision to be made



#### Divide and conquer Break it down, understand it, and put it back together

"The spirit of decision analysis is divide and conquer:

decompose a complex problem into simpler problems,

get one's thinking straight on these simpler problems,

paste these analyses together with logical glue, and


come out with a program of action for the complex problem"

-- Howard Raiffa



## Influence diagrams are a useful tool for model building

t = time s = state



## Influence diagrams also show what data you need

- The information nodes with no parents show what data you need to populate the model
- Data come from a variety of sources
  - In house clinical trial data
  - External databases
  - Literature
  - Expert knowledge
  - Other modeling activities

•

To get these data you need a strong network of experts, who can identify relevant data sources and can give their opinions **UNOVARTIS** 

### Continuous parsimony

A simple model can be an underlying framework for drug development


#### Good modeling is not made unnecessarily complicated and is a continuous process

- "Everything should be as simple as it can be but not simpler" -- Albert Einstein
- "Any fool can make something complicated. It takes a genius to make it simple" -- Woody Guthrie



### Work hard to make your model easy


- Building a simple model is difficult
  - Models tend to get overly complicated
  - A simple elegant model require a lot of thought
  - Large part of it is tacit knowledge that you learn by doing
- Tips for keeping it simple
  - Always remember the decision context and keep focused on it
  - Don't try to make a Eierlegende Wollmilchsau ("Egg-Laying Wool-Milk-Sow")
  - Resist the temptation for "scope creep"





🔥 NOVARTIS

### A simple model is easier to maintain and explain



- reimbursement
  - Used for early interaction with HA and HTA organizations

16 | Health Economic Models can support drug development decisions | Richard Nixon | 2013 June 4

\rm 🔥 NOVARTIS

## Communication


"People decide, not models" -- Larry Phillips

#### **Good modeling facilitates communication**

- Modeling is about bringing clarity to decisions and supporting decision makers, not replacing them
- Sensitivity analysis is especially important in early health economic models as there is a lot of uncertainty
  - Perhaps less need for probabilistic sensitivity analysis at this stage



#### Waterfall plot shows the main value drivers Assume a Willingness—to-pay of 35K Euro



18 | Health Economic Models can support drug development decisions | Richard Nixon | 2013 June 4

#### **U** NOVARTIS

## A note on how to partition costs and utilities (1/2)


- At a given time we have
  - C<sub>i,D</sub> and C<sub>i,S</sub> for the cost from component *i* given Drug or SoC
  - U<sub>i,D</sub> and U<sub>i,S</sub> for the utility from component *i* given Drug or SoC, given that the patient is alive
  - $P_{D}$  and  $P_{S}$  for the probability of being alive given Drug or SoC
- The model has been structured in such a way that the total utility can be writen as
  - $U_{TOT,D} = \Sigma U_{i,D}$
  - The incremental cost for a component is C<sub>i,D</sub> C<sub>i,S</sub>
  - The incremental utility (accounting for death) **overall** is  $P_D \Sigma U_{i,D} P_S \Sigma U_{i,S}$

#### How is the contribution of each utility component to the over all incremental utility obtained?



### A note on how to partition costs and utilities (2/2)

Graphical representation of incremental overall utility




Death:  $\frac{1}{2}(P_D - P_S)(\sum U_{i,D} + \sum U_{i,S})$ Total Utility:  $\frac{1}{2}(P_D + P_S)(\sum U_{i,D} - \sum U_{i,S})$ 

Utility from comp *i*:  $\frac{1}{2}(P_D + P_S)(U_{i,D} - U_{i,S})$ 



### Tornado plots show a one-way sensitivity analysis



- The base case price is 660 Euro PPPM
- Parameters values at base case are shown under each bar
- Sensitivity analysis: The parameter values are changed one at a time. The new values are shown at the ends of each bar
- The price increases most when
  - The event rate of the population is larger
  - The time horizon is longer
  - The relative risk of an event given Drug (compared to SoC) is smaller
  - Utility gain when perceive protected is larger



Wed Nov 07 14:23:32 2012

1000

1500

21 | Health Economic Models can support drug development decisions | Richard Nixon | 2013 June 4


500

0

-500

#### **U** NOVARTIS


## Two-way sensitivity analysis of most important uncertainties



- Utility gain when perceive protected on the x-axis. Base case = 0.1
- Each line shows the RR of an event given successful Drug vs. SoC . Base case = 0.6
- Price PPM of Drug is 660 Euro
  - Price of 800 Euro is achievable if the RR of an event given successful treatment is decreased to 0.5, or utility gain increases to 0.14
- Time horizon is on the x-axis
- Each line shows the event rates. Base case = 1 per year
- Benefits are only realized in the long term because the costs are upfront
- In a population with an event rate of 0.5 per year, the supported price of the drug reduces to 280 Euro



## Four-way sensitivity analysis of most important uncertainties



- The four most important parameters are all varied together.
  - Red dot is the base case with a drug price of 660 Euro PPPM.
  - Different time horizons are given in the columns.
  - Different population event rates are given in the rows.
  - The utility gain when perceive protected is on the x-axis.
  - Each line shows the time a patient is event free until they perceive they are protected.
- Can assess what would need to happed to justify a given drug price.

23 | Health Economic Models can support drug development decisions | Richard Nixon | 2013 June 4

#### **U** NOVARTIS

## Revisit the original decisions to be made

Distill big difficult decisions down to smaller simpler decisions

- Should development be continued?
  - What price could be justified for the drug to be cost-effective?
  - *Is there a cost-effective sub-population?*
  - The drug has an expected value of 660 Euro PPPM in a population with an event rate of 1 per year, increasing to 1100 Euro in a population with double this rate
- What do we need to measure in the development program if we continue?
  - What are the key value drivers of the drug?
  - To demonstrate the value of the drug it is crucial to measure the QALY gains from reduced perception of risk and the resource use in emergency units



## Skills in a statistician's toolbox can be readily applied in this area

- Traditional (pharma) statistician role
  - Close regard for regulator guidelines is important for confirmatory trials
- Opportunity for expansion of statistician role
  - Model-based drug development needs a different mindset and different methodologies
- Statistical training is readily transferable
  - Clear logical structuring, comfortable with complexity, elegant mindset, quantitative skills, and understanding of uncertainty



### Conclusions

- Need to demonstrate the value of a new drug to payers
- Health economic decision models can support decision making during the drug development process
  - Supporting go no-go decisions
  - Population section
  - Identifying what information needs to be collected at Phase III
  - Assessing the price that can be justified for the drug
- The decisions and decision makers during drug development are different from reimbursement
- Statisticians are well placed to support this process

